RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q3 FY24 results · Oct–Dec 2023
RPG Life Sciences reported revenue from operations of ₹153.70 crore (up 17.7% from Q3 FY23) and net profit of ₹26.46 crore (up 38.5% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a standalone basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 153.70 | 130.60 | +17.7% | 153.58 | +0.1% |
| Other income | 1.92 | 0.51 | +276.5% | 1.83 | +4.9% |
| Total income | 155.62 | 131.11 | +18.7% | 155.41 | +0.1% |
| Profit before tax | 35.54 | 25.74 | +38.1% | 34.79 | +2.2% |
| Net profit for the period | 26.46 | 19.11 | +38.5% | 25.86 | +2.3% |
| EPS, basic (₹) | 16.00 | 11.56 | +38.4% | 15.64 | +2.3% |
| Net margin (%) | 17.2 | 14.6 | 16.8 |
Standalone
- Filed with BSE
- 16 Feb 2024, 14:52 IST
- Board meeting
- 01 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE